| Literature DB >> 32411198 |
Jing Zhang1, Zheng-Ying Wang1, Jing-Ping Zhang2, Hua Zhou3, Zan Ding3.
Abstract
BACKGROUND: Serum alanine aminotransferase (ALT) activity was measured not only to detect liver disease, but also to monitor overall health. The purpose of this study was to obtain the prevalence of elevated ALT levels among adolescents.Entities:
Year: 2020 PMID: 32411198 PMCID: PMC7204184 DOI: 10.1155/2020/4240380
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Baseline descriptive statistics for serum alanine aminotransferase levels (U/L) stratified by gender among the adolescents (aged 10–17 years) of Shenzhen, China, 2017–2018.
| Sample |
| Mean | SD | Min | Percentiles | Max | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5th | 10th | 25th | 50th | 75th | 90th | 95th | 99th | ||||||
| Overall (years) | |||||||||||||
| 10.0–10.9 | 60 | 11.25 | 5.04 | 3 | 6 | 7 | 9 | 10 | 13 | 14 | 15 | 33 | 39 |
| 11.0–11.9 | 967 | 12.23 | 6.85 | 3 | 7 | 8 | 9 | 11 | 14 | 17 | 20 | 38 | 141 |
| 12.0–12.9 | 1511 | 12.67 | 9.29 | 1 | 7 | 8 | 9 | 11 | 13 | 18 | 22 | 48 | 206 |
| 13.0–13.9 | 471 | 14.85 | 21.84 | 3 | 7 | 8 | 9 | 12 | 15 | 20 | 27 | 76 | 415 |
| 14.0–14.9 | 1101 | 14.21 | 12.76 | 1 | 7 | 8 | 9 | 11 | 14 | 22 | 33 | 68 | 193 |
| 15.0–15.9 | 1789 | 15.57 | 19.59 | 3 | 7 | 8 | 9 | 11 | 16 | 24 | 35 | 75 | 495 |
| 16.0–16.9 | 1136 | 15.80 | 15.54 | 3 | 7 | 7 | 9 | 12 | 16 | 25 | 36 | 81 | 213 |
| 17.0–17.9 | 246 | 15.29 | 11.38 | 4 | 7 | 8 | 9 | 12 | 16 | 25 | 33 | 65 | 93 |
| 10.0–17.9 | 7281 | 14.26 | 14.77 | 1 | 7 | 8 | 9 | 11 | 15 | 21 | 30 | 67 | 495 |
| Boys (years) | |||||||||||||
| 10.0–10.9 | 33 | 11.21 | 5.58 | 6 | 6 | 7 | 9 | 10 | 12 | 14 | 15 | 31 | 39 |
| 11.0–11.9 | 490 | 13.36 | 8.52 | 4 | 7 | 8 | 10 | 12 | 15 | 18 | 23 | 46 | 141 |
| 12.0–12.9 | 899 | 13.39 | 8.80 | 2 | 7 | 8 | 9 | 11 | 14 | 19 | 25 | 50 | 113 |
| 13.0–13.9 | 269 | 13.17 | 10.12 | 4 | 7 | 8 | 9 | 11 | 14 | 19 | 25 | 50 | 138 |
| 14.0–14.9 | 546 | 16.74 | 16.36 | 1 | 7 | 8 | 10 | 12 | 18 | 27 | 40 | 92 | 193 |
| 15.0–15.9 | 1017 | 18.23 | 24.31 | 3 | 7 | 8 | 10 | 13 | 18 | 29 | 40 | 116 | 495 |
| 16.0–16.9 | 624 | 18.51 | 19.45 | 3 | 7 | 8 | 10 | 13 | 19 | 33 | 50 | 102 | 213 |
| 17.0–17.9 | 136 | 17.16 | 13.62 | 4 | 7 | 8 | 10 | 12 | 18 | 32 | 49 | 65 | 93 |
| 10.0–17.9 | 4014 | 15.96 | 17.02 | 1 | 7 | 8 | 10 | 12 | 16 | 25 | 37 | 79 | 495 |
| Girls (years) | |||||||||||||
| 10.0–10.9 | 27 | 11.30 | 4.39 | 3 | 7 | 7 | 10 | 11 | 13 | 14 | 16 | 25 | 28 |
| 11.0–11.9 | 477 | 11.07 | 4.24 | 3 | 6 | 7 | 9 | 10 | 12 | 16 | 18 | 27 | 40 |
| 12.0–12.9 | 612 | 11.62 | 9.89 | 1 | 6 | 7 | 9 | 10 | 12 | 16 | 19 | 43 | 206 |
| 13.0–13.9 | 202 | 17.07 | 31.15 | 3 | 7 | 8 | 9 | 12 | 16 | 22 | 30 | 96 | 415 |
| 14.0–14.9 | 555 | 11.72 | 6.89 | 2 | 6 | 7 | 8 | 10 | 13 | 16 | 21 | 43 | 68 |
| 15.0–15.9 | 772 | 12.06 | 9.48 | 3 | 6 | 7 | 8 | 10 | 13 | 18 | 23 | 46 | 186 |
| 16.0–16.9 | 512 | 12.51 | 7.44 | 3 | 7 | 7 | 9 | 11 | 14 | 20 | 24 | 36 | 88 |
| 17.0–17.9 | 110 | 12.98 | 7.17 | 4 | 7 | 8 | 9 | 12 | 15 | 19 | 22 | 29 | 69 |
| 10.0–17.9 | 3267 | 12.18 | 11.06 | 1 | 6 | 7 | 9 | 10 | 13 | 17 | 22 | 46 | 415 |
ALT: alanine aminotransferase; SD: standard deviation.
Figure 1Crude age-prevalence of elevated alanine aminotransferase (ALT) based on the diagnostic criteria I (a) and II (b) among the adolescents of Shenzhen, China, 2017–2018.
Figure 2Standardized prevalence of elevated alanine aminotransferase (ALT) among the adolescents of Shenzhen, China, 2017–2018, diagnosed with both the criteria I and II, based on the 2010 Shenzhen Census Population (a) and the 2010 Chinese National Census Population (b).
Crude age-prevalence of elevated alanine aminotransferase (ALT) stratified by gender among the adolescents of Shenzhen, China, 2017–2018, separately based on the diagnostic criteria I and II.
| Age (years) | Criterion I† | Criterion II‡ | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall | Boys | Girls |
| Overall | Boys | Girls |
| |
| 10–17 | 7.11 (6.52-7.7) | 6.88 (6.09-7.66) | 7.41 (6.51-8.31) | 0.380 | 2.72 (2.35-3.09) | 3.96 (3.36-4.56) | 1.19 (0.82-1.57) |
|
| 10–11 | 3.60 (2.46-4.74) | 2.87 (1.44-4.30) | 4.37 (2.58-6.15) | 0.198 | 0.78 (0.24-1.32) | 1.53 (0.48-2.58) | 0 (0-0) |
|
| 12 | 4.37 (3.34-5.40) | 4.00 (2.72-5.29) | 4.90 (3.19-6.61) | 0.402 | 1.79 (1.12-2.45) | 2.22 (1.26-3.19) | 1.14 (0.30-1.99) | 0.119 |
| 13 | 7.01 (4.70-9.31) | 2.97 (0.94-5.00) | 12.38 (7.83-16.92) | <0.001 | 2.76 (1.28-4.24) | 1.49 (0.04-2.93) | 4.46 (1.61-7.30) |
|
| 14 | 7.54 (5.98-9.10) | 8.24 (5.94-10.55) | 6.85 (4.75-8.95) | 0.381 | 3.00 (1.99-4.00) | 4.76 (2.98-6.55) | 1.26 (0.33-2.19) |
|
| 15 | 8.66 (7.36-9.97) | 8.95 (7.19-10.70) | 8.29 (6.35-10.24) | 0.624 | 3.41 (2.57-4.25) | 5.01 (3.67-6.36) | 1.30 (0.50-2.09) |
|
| 16 | 10.39 (8.61-12.16) | 10.58 (8.16-12.99) | 10.16 (7.54-12.77) | 0.817 | 4.05 (2.90-5.20) | 6.57 (4.63-8.51) | 0.98 (0.12-1.83) |
|
| 17 | 10.57 (6.73-14.41) | 11.03 (5.76-16.29) | 10.00 (4.39-15.61) | 0.794 | 4.07 (1.60-6.53) | 6.62 (2.44-10.8) | 0.91 (0-2.68) |
|
The prevalence of elevated ALT is expressed as % (95% confidence interval). †Diagnostic criterion I: >30 U/L for boys and >19 U/L for girls. ‡Diagnostic criterion II: >40 U/L for boys and girls. ∗P < 0.001 comparing girls with boys by Pearson's chi-square test.
Univariate and multivariate logistic regression analyses with elevated alanine aminotransferase (ALT) as the outcome variable, based on the diagnostic criterion I (>30 U/L for boys and >19 U/L for girls).
| Variable | Univariate analysis | Multivariate analysisa | ||||
|---|---|---|---|---|---|---|
| Wald test | OR (95% CI) |
| Wald test | OR (95% CI) |
| |
| Girls (vs. boys) | 0.770 | 1.08 (0.91-1.30) | 0.380 | 23.587 | 1.65 (1.35-2.03) | <0.001 |
| Age (years) | 62.625 | <0.001 | 34.547 | <0.001 | ||
| 10–11 | 1.00 | 1.00 | ||||
| 12 | 0.917 | 1.22 (0.81-1.84) | 0.338 | 1.295 | 1.29 (0.83-2.01) | 0.255 |
| 13 | 8.108 | 2.02 (1.24-3.27) | 0.004 | 7.431 | 2.06 (1.23-3.47) | 0.006 |
| 14 | 14.816 | 2.18 (1.47-3.25) | <0.001 | 5.601 | 1.68 (1.09-2.59) | 0.018 |
| 15 | 24.716 | 2.54 (1.76-3.66) | <0.001 | 12.089 | 2.03 (1.36-3.02) | 0.001 |
| 16 | 34.169 | 3.10 (2.12-4.53) | <0.001 | 19.535 | 2.53 (1.67-3.83) | <0.001 |
| 17 | 18.656 | 3.16 (1.88-5.33) | <0.001 | 15.973 | 3.17 (1.80-5.58) | <0.001 |
| Constant | — | — | — | 667.963 | — | <0.001 |
Boys or 10–11 years as the reference group; OR (95% CI): odds ratio (95% confidence interval). aAdjusted for gender, age, and body mass index using a multivariable logistic regression analysis.
Univariate and multivariate logistic regression analyses with elevated alanine aminotransferase (ALT) as the outcome variable, based on the diagnostic criterion II (>40 U/L for boys and girls).
| Variable | Univariate analysis | Multivariate analysisa | ||||
|---|---|---|---|---|---|---|
| Wald test | OR (95% CI) |
| Wald test | OR (95% CI) |
| |
| Girls (vs. boys) | 46.388 | 0.29 (0.21-0.42) | <0.001 | 21.129 | 0.42 (0.29-0.60) | <0.001 |
| Age (years) | 28.711 | <0.001 | 16.540 | 0.011 | ||
| 10–11 | 1.00 | 1.00 | ||||
| 12 | 4.315 | 2.32 (1.05-5.12) | 0.038 | 3.872 | 2.32 (1.00-5.38) | 0.049 |
| 13 | 8.054 | 3.62 (1.49-8.78) | 0.005 | 9.492 | 4.31 (1.70-10.92) | 0.002 |
| 14 | 11.940 | 3.94 (1.81-8.56) | 0.001 | 7.945 | 3.24 (1.43-7.35) | 0.005 |
| 15 | 15.808 | 4.50 (2.14-9.43) | <0.001 | 8.593 | 3.21 (1.47-6.99) | 0.003 |
| 16 | 19.030 | 5.38 (2.53-11.44) | <0.001 | 11.086 | 3.90 (1.75-8.69) | 0.001 |
| 17 | 12.346 | 5.40 (2.11-13.82) | <0.001 | 10.645 | 5.34 (1.95-14.60) | 0.001 |
| Constant | — | — | — | 268.333 | — | <0.001 |
Boys or 10–11 years as the reference group; OR (95% CI): odds ratio (95% confidence interval). aAdjusted for gender, age, and body mass index using a multivariable logistic regression analysis.
Summaries of the prevalence of elevated ALT among adolescents for serum alanine aminotransferase (ALT) worldwide.
| No. | Study | Country | Target population | Age (years) | Sample size | Definition (U/L) | Prevalence of elevated ALT |
|---|---|---|---|---|---|---|---|
| 1 | Kim et al. [ | Korea | Adolescents | 10-18 | 8455 | >30 | 5.3% in total |
| >40 | 2.8% in total | ||||||
| >33 for boys | 5.4% in total | ||||||
|
| |||||||
| 2 | Ruhl and Everhart [ | U.S. | Adolescents | 12-19 | 9361 | >31 for boys | 10.8% am and 11.3% pm in boys |
|
| |||||||
| 3 | Kong et al. [ | China | Adolescents | 12-18 | 2102 | >40 | 3.2% in total |
| >30 | 5.9% in total | ||||||
|
| |||||||
| 4 | Fraser et al. [ | U.S. | Adolescents | 12-19 | 5586 | >30 | 8.0% in total |
| >40 | 3.6% in total | ||||||
|
| |||||||
| 5 | Strauss et al. [ | U.S. | Overweight and obese adolescents | 12-18 | 2450 | >30 | 6% in overweight |
|
| |||||||
| 6 | Park et al. [ | Korea | Adolescents | 10-19 | 1594 | >40 | 3.6% in boys |
|
| |||||||
| 7 | Wu et al. [ | China | Students | 12-24 | 6997 | ≥40 | 3.1% in total |
|
| |||||||
| 8 | Park et al. [ | Korea | Adolescents | 12-18 | 1591 | >33 for boys | 5.9% in total |
|
| |||||||
| 9 | Fermin et al. [ | U.S. | Adolescents | 12-19 | 5411 | >30 | 9.14% in total |
| >22 for girls | 16.25% in total | ||||||
|
| |||||||
| 10 | DeBoer et al. [ | U.S. | Adolescents | 12-19 | 4124 | >30 | 9.0% in total |
|
| |||||||
| 11 | Ramirez-Lopez et al. [ | Mexico | Adolescents | 14-19 | 674 | >40 | 3.0% in total |
|
| |||||||
| 12 | Purcell et al. [ | Mexico | Youth | 8-19 | 1262 | >40 | 9.8% in boys |
|
| |||||||
| 13 | Elizondo-Montemayor et al. [ | Mexico | Obese and overweight children | 6-12 | 236 | >40 | 17.7% in total |
|
| |||||||
| 14 | Samani et al. [ | Iran | Children and adolescents | 6-18 | 1172 | >30 for boys | 4.9% in boys |
|
| |||||||
| 15 | Wang et al. [ | Korea | Healthy adolescents | 10-18 | 1785 | >24.1 for boys | 14.9% in boys |
|
| |||||||
| 16 | van Vliet et al. [ | Netherlands | Overweight and obese children | 3-18 | 443 | >30 | 20.3% in total |
|
| |||||||
| 17 | Park et al. [ | Korea | Adolescents | 10-18 | 2242 | >30 for boys | 7.9% in boys |